The FDA cleared Genentech’s Tecentriq in combination with Avastin and chemotherapy for treatment of certain forms of metastatic lung cancer.

The approval specifically applies to first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) and no EFGR or ALK genomic tumor aberrations.

The agency based its approval on a Phase 3 trial that showed the regimen led to patients living significantly longer than with Avastin and chemotherapy alone. Tecentriq is already cleared by the FDA to treat metastatic NSCLC patients who have disease progression during or after platinum chemotherapy.